Influenza/RSV by PCR Test at Chughtai Lab

Influenza/RSV by PCR at Chughtai Lab

The Influenza/RSV by PCR test at Chughtai Lab is a highly sophisticated molecular diagnostic assay designed to rapidly and accurately detect the genetic material of Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) in patients presenting with acute respiratory symptoms. Respiratory tract infections caused by these viral pathogens represent a significant clinical burden globally and in Pakistan, particularly during the winter months when viral circulation peaks. Because the clinical presentations of Influenza and RSV overlap significantly with other viral and bacterial respiratory infections, definitive diagnosis based on clinical symptoms alone is highly challenging. This molecular panel utilizes Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) technology, which is widely recognized as the gold standard in diagnostic virology due to its exceptional sensitivity, specificity, and rapid turnaround time compared to traditional viral cultures and rapid antigen detection tests (RADTs).

The primary anatomical region evaluated during this diagnostic procedure is the upper respiratory tract, specifically the nasopharyngeal mucosa, which serves as the primary site of viral replication for these pathogens. By obtaining a nasopharyngeal specimen, clinicians can directly access the epithelial cells and secretions harboring the viral particles. The clinical importance of differentiating between Influenza A, Influenza B, and RSV cannot be overstated. While all three viruses can cause severe respiratory illness, their clinical management, therapeutic options, and public health implications differ substantially. For instance, early detection of Influenza allows for the timely administration of specific antiviral therapies, such as neuraminidase inhibitors (e.g., oseltamivir), which are most effective when initiated within 48 hours of symptom onset. Conversely, RSV management is primarily supportive, though rapid identification is crucial for infection control in healthcare settings, particularly in pediatric and neonatal wards where RSV can cause life-threatening bronchiolitis and pneumonia. By providing a definitive molecular diagnosis, the Influenza/RSV by PCR test at Chughtai Lab empowers healthcare providers to make informed decisions regarding antiviral therapy, avoid unnecessary antibiotic prescription, and implement appropriate infection control measures to prevent nosocomial transmission.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the integrity of the specimen and the accuracy of the molecular test results. Patients undergoing the Influenza/RSV by PCR test at Chughtai Lab should observe the following guidelines:

• No Fasting Required: There is no requirement for fasting prior to this test. Patients can consume food and drinks normally before the sample collection.
• Avoid Nasal Medications: Patients must avoid using nasal sprays, drops, gels, or nasal washes for at least 4 to 6 hours before the test, as these substances can dilute the viral load or contain chemical agents that interfere with the PCR amplification process.
• Inform the Clinician: It is critical to inform the healthcare professional about any recent antiviral medications, nasal surgeries, or chronic nasal conditions (such as severe deviated nasal septum) before the procedure begins.
• Symptom Reporting: Provide a brief history of the onset of symptoms, such as fever, cough, sore throat, or respiratory distress, to assist in clinical correlation.

During the Procedure

The sample collection process is performed by trained phlebotomists or nursing staff at Chughtai Lab, adhering to strict biosafety and infection control protocols to prevent cross-contamination. The procedure involves the following steps:

• Patient Positioning: The patient is seated comfortably, and their head is tilted back slightly (approximately 70 degrees) to facilitate access to the nasal passage.
• Equipment: A sterile, flexible-shaft flocked swab made of synthetic material (such as dacron or polyester) is used. Cotton-tipped or calcium alginate swabs are avoided as they contain substances that can inhibit PCR reactions.
• Sample Collection: The swab is gently inserted through the nostril parallel to the palate until resistance is met, indicating contact with the posterior nasopharynx. The depth of insertion is equivalent to the distance from the nostril to the outer opening of the ear.
• Swab Rotation: The swab is gently rubbed and rolled over the surface of the posterior nasopharynx for several seconds to collect cellular material and secretions containing the viral particles.
• Removal and Transport: The swab is slowly removed and immediately placed into a vial containing Viral Transport Medium (VTM). The shaft of the swab is snapped off at the designated break point, and the vial is tightly capped.
• Safety and Comfort: The procedure may cause brief discomfort, a transient gag reflex, or watering of the eyes, but it is not painful and is completed within a few seconds. The specimen is labeled immediately with the patient’s unique identification details and transported under controlled temperature conditions to the molecular diagnostic laboratory.

When is an Influenza/RSV by PCR Performed?

Severe Acute Respiratory Infection

Physicians request this molecular test when a patient presents with signs of severe acute respiratory infection (SARI), including high-grade fever, persistent cough, and shortness of breath. Rapid PCR testing helps identify whether the severe illness is driven by Influenza or RSV, allowing for immediate clinical intervention and monitoring for potential complications like secondary bacterial pneumonia.

Pediatric Respiratory Distress

In infants and young children presenting with wheezing, rapid breathing, flaring of the nostrils, and chest retractions, this test is critical. RSV is the leading cause of bronchiolitis and pneumonia in infants under one year of age. Identifying RSV early helps pediatricians manage hydration, oxygenation, and avoid the inappropriate use of bronchodilators or antibiotics.

Geriatric and Immunocompromised Surveillance

Elderly patients and individuals with compromised immune systems (such as oncology patients, transplant recipients, or those on immunosuppressive therapies) are at high risk for severe complications from respiratory viruses. This test is performed at the earliest sign of mild respiratory symptoms in these vulnerable groups to initiate prompt antiviral treatment and prevent progression to lower respiratory tract disease.

Differential Diagnosis of Winter Illnesses

During the peak viral season, multiple respiratory pathogens circulate simultaneously. Clinicians order the Influenza/RSV PCR panel to differentiate between Influenza A, Influenza B, RSV, and other respiratory pathogens. This precise differentiation is essential because the clinical management pathways for these infections are distinct, and accurate diagnosis prevents empirical over-treatment.

Outbreak Management and Infection Control

In institutional settings such as hospitals, nursing homes, schools, and daycare centers, a rapid and accurate diagnosis of Influenza or RSV is vital for public health. This test is performed to identify index cases quickly, enabling the implementation of cohorting, isolation protocols, and prophylactic antiviral measures to contain localized outbreaks.

What Does an Influenza/RSV by PCR Detect?

The Influenza/RSV by PCR test is designed to detect specific nucleic acid sequences (RNA) of the target viruses. The assay is capable of identifying and distinguishing between the following clinical findings and parameters:

• Presence of Influenza A viral RNA
• Presence of Influenza B viral RNA
• Presence of Respiratory Syncytial Virus (RSV) viral RNA
• Co-infection with Influenza A and RSV
• Co-infection with Influenza B and RSV
• Co-infection with Influenza A and Influenza B
• Absence of Influenza A, Influenza B, and RSV viral RNA (Negative result)
• Inadequate specimen collection (indicated by the absence of the human internal control gene)
• Presence of PCR inhibitors in the sample
• Influenza A subtype H1N1 (if subtyping is included in the assay panel)
• Influenza A subtype H3N2 (if subtyping is included)
• RSV Subtype A genetic material
• RSV Subtype B genetic material
• High viral load (semi-quantitatively indicated by low Cycle Threshold values)
• Low viral load (semi-quantitatively indicated by high Cycle Threshold values)
• Equivocal or borderline positive results requiring retesting
• Specimen degradation due to improper transport or storage
• Presence of viral RNA in asymptomatic carriers or during the incubation phase
• Persistent viral shedding post-recovery
• Viral genetic variants compatible with the assay’s primer designs

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to delivering highly accurate diagnostic reports within the shortest possible timeframe, recognizing the critical nature of respiratory viral infections. The turnaround time for the Influenza/RSV by PCR test is typically within 24 to 48 hours from the time of sample receipt at the central molecular laboratory. Patients and healthcare providers can access reports conveniently through multiple digital channels. Reports can be viewed and downloaded directly from the official Chughtai Lab website portal or via the Chughtai Lab mobile application. Additionally, patients receive automated notifications and can obtain their reports through WhatsApp or by visiting any of the numerous Chughtai Lab collection centers across Pakistan.

Influenza/RSV by PCR Findings Overview